Qiagen

                   

Deals roundup: HealthTronics reaffirms bid of $2.28 a share for Endocare

tmcnet.com     yesterday          

Deals roundup: HealthTronics reaffirms bid of $2.28 a share for Endocare By DON LONGMedical Device Daily National Editor HealthTronics (Austin, Texas) is being a persistent bidder ? but showing the kind of persistence...                    

comments

Invitrogen licenses amplification technology to three life science companies

pharmaceutical-business-review.com     yesterday          

Invitrogen, a provider of life science technologies for research, production and diagnostics, has signed non-exclusive agreements with New England Biolabs, Qiagen and Kirkegaard & Perry Laboratories, whereby the companies...                    

comments

Thomas Weisel Partners Hosts Annual Healthcare Conference

redorbit.com     Sep 3, 2008   2 related          

Posted on: Wednesday, 3 September 2008, 06:00 CDT Thomas Weisel Partners (NASDAQ: TWPG) (TSX: TWP), a global growth-focused investment bank, will host its Annual Healthcare Conference, September 3-5 at the Four Seasons...                    

comments

DGAP-CMS: QIAGEN N.V.: Release according to Article 30e of the WpHG [the German Securities...

finanznachrichten.de     Sep 3, 2008   4 related          

DJ DGAP-CMS: QIAGEN N.V.: Release according to Article 30e of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution QIAGEN N.V. / Third country release according to Article 30e Para....                    

comments

DGAP-NVR: Qiagen N.V.: Release according to Article 26a of the WpHG [the German Securities...

finanznachrichten.de     Aug 29, 2008   14 related          

DJ DGAP-NVR: Qiagen N.V.: Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution QIAGEN N.V. / Total Voting Rights announcement 29.08.2008 Total...                    

comments

Qiagen introduces new HIV diagnostic assay

pharmaceutical-business-review.com     Aug 21, 2008          

Qiagen has launched a new molecular diagnostic test to type the HLA-B5701 allele, a genetic variation in the human leucocyte antigen system. The newly launched test complements a larger personalized medicine portfolio which...                    

comments

                   

The Great American Yard Sale. (Time.com)

yahoo.com     Aug 19, 2008   1 related          

By JEFF ISRAELY/PARIS 2 hours, 5 minutes ago When Belgian-based, Brazilian-controlled InBev launched a hostile offer for American beer king Anheuser-Busch last month, xenophobia quickly foamed to the top. It's everything from...                    

comments

                   
genengnews.com: Genetic Engineering genengnews.com

QIAGEN Unveils Diagnostic Assay in the EU to Detect Genetic Variation Causing Adverse Reactions...

genengnews.com     Aug 19, 2008   10 related          

HLA-B*5701 biomarker indicates risk for severe adverse reactions to Abacavir / Experts expect more tests for similar markers in the future Venlo, The Netherlands - QIAGEN (Nasdaq: QGEN; Frankfurt Prime Standard: QIA) today...                    

comments

BellwetherReport.com Analyst Report on QGEN, SOLF, CMCSA and ZVUE

marketwire.com     Aug 14, 2008   11 related          

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by The Bellwether Report. TORONTO--(Marketwire - August 14, 2008) - BellwetherReport.com is the leading online financial newsletter for investors seeking top...                    

comments

                   

Geneart AG: GENEART AG Combines Net Sales Growth with Strong Earnings in the 1st Half- year of 2008

marketwire.com     Aug 13, 2008   5 related          

REGENSBURG, GERMANY--(Marketwire - Supported by the market development, the GENEART AG was again able to significantly increase its net sales and operating result (EBIT) in the 1st half of 2008 while expanding its leading...                    

comments

1 2 3 4 5 next »